MAO

MAO-IN-1 is a potent monoamine oxidase B (MAO B) inhibitor (IC50: 20 nM) for the study of neurologically related diseases.

MAO-B-IN-8 is a highly potent and reversible inhibitor of monoamine oxidase-B (MAO-B), also inhibiting microglial production of neuroinflammatory mediators. This compound is specifically designed for research on neurodegenerative diseases [1].

AChE/BChE/MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE, and MAO-B that crosses the blood-brain barrier, exhibiting inhibitory effects on hAChE, hBChE, and hMAO-B with IC50s of 7.31, 0.56, and 26.1 μM, respectively. [AChE/BChE/MAO-B-IN-1] had a neuroprotective effect and was not significantly cytotoxic.

MAO-B-IN-30 is a selective and potent MAO-B inhibitor that crosses the blood-brain barrier with antiproliferative activity and inhibits both MAO-A and MAO-B.MAO-B-IN-30 reduces the levels of TNF-alpha, IL-6, and NF-kB in organisms, and can be used to study Parkinson's-type neurological disorders.

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

MAO-B-IN-5 is a potent, selective, and orally active MAO-B inhibitor with an IC50 of 0.204 μM, showing potential for research in Parkinson's disease (PD) [1].

hMAO-B-IN-32 is a potent hMAO-B selective inhibitor with an IC50 of 45.52 μM.

MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC50 values of 0.51 μM and 7.00 μM, respectively. It attenuates H2O2-induced cellular damage due to its strong ROS scavenging properties.

MAO-IN-M30 dihydrochloride is a highly potent non-selective inhibitor of MAO-A and MAO-B (IC50 < 0.1 μM). MAO-IN-M30 dihydrochloride is orally active and can cross the blood-brain barrier. It is an effective iron chelator and free radical scavenger. MAO-IN-M30 dihydrochloride has neuroprotective activity in in vitro and in vivo models of Parkinson's disease (PD). It increases brain dopamine, serotonin and norepinephrine and can serve as a lead drug for the development of multifunctional drugs to treat various neurodegenerative diseases.

MAO-B ligand-1 is a selective MAO-B inhibitor.

2614W94 is a selective inhibitor of MAO-A with IC50 of 5 nM and Ki of 1.6 nM.

CX-157 (KP 157) is a novel monoamine oxidase-A (MAO-A) inhibitor for the study of depression-like neurological disorders and cancer.

BW-1370U87 is a reversible competitive monoamine oxidase-A inhibitor for the study of depression and other CNS disorders.

Esuprone (LU-43839) is a novel reversible and highly selective MAO-A inhibitor with anticonvulsant activity for the treatment of depression.

Sembragiline (EVT-302) is a selective MAO-B inhibitor for the study of Alzheimer's disease (AD).

Ladostigil (Ladostigil free base) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO) with inhibitory effects on MAO-B and AChE, with IC50 values of 37.1 and 31.8 μM, respectively.Ladostigil possesses anti-inflammatory, antioxidant, and neuroprotective activities, and may be used in studies of depression and Alzheimer's disease.

Femoxetine is a 5-HT inhibitor with antidepressant activity that potentiates morphine-induced anti-injury feelings and inhibits MAO-A and MAO-B required for the production of high exercise capacity in mice.

Atibeprone is a MAO-B inhibitor with antidepressant activity for the study of Parkinson's disease.

Pargyline (Pargylamine) is a monoamine oxidase inhibitor with antihypertensive properties.

Allylthiourea (Thiosinamine), a metabolic inhibitor, specifically suppresses ammonia oxidation.

Furazolidone (Furoxone), a nitrofuran derivative, inhibits AML1-ETO transformed cells with IC50 value of 12.7 μM. It is antibacterial and antiprotozoal activity,

Iproniazid Phosphate is a non-selective, irreversible monoamine oxidase inhibitor (MAOI).

Tranylcypromine (2-PCPA) hydrochloride (SKF-385 HCl), a Monoamine Oxidase inhibitor, is effective in the treatment of major depression, dysthymic disorder, and atypical depression.

Hydroxylamine hydrochloride(Hydroxylammonium chloride) is a selective and potent monoamine oxidase (MAO) inhibitor with inhibitory effects on platelet aggregation.Hydroxylamine hydrochloride is an intermediate in organic synthesis and can be used to synthesize other active compounds.